Citations

Clear

1011 citation(s) found for "Barry, WT".

Practical consensus recommendations for polytherapy involving stiripentol in Dravet syndrome: A nominal group approach
Cross, J. Helen, Nabbout, Rima, Gidal, Barry E., Sullivan, Joseph, Wirrell, Elaine, Wirrell, Elaine , Cross, J. Helen , Gidal, Barry E. , Cross, Helen J , Nabbout, Rima , Gidal, Barry , Sullivan, Joseph , Wirrell, Elaine C , Nabbout, Rima

Mayo Clinic

Epilepsia Open | March 18, 2026 | Volume: 11 | Issue: 3 | Pages: 833-846

10.1002/epi4.70245 | PMID 41848774 Get It

Abstract Objectives Dravet syndrome (DS) is a drug‐resistant developmental and epileptic encephalopathy, often requiring three or more antiseizure medications (ASMs). Consequently, the therapeutic landscape is highly complex, combining DS‐specific agents (stiripentol, STP; cannabidiol, CBD; fenfluramine, FFA), non‐specific ASMs, and non‐pharmacologic options such as dietary therapy or neuromodulation. In addition, recognition of patients' changing needs across the lifespan, together with the essential contribution of caregiver education to effective treatment oversight—including awareness of potential drug–drug interactions and adverse events—emphasizes the value of an integrated and forward‐looking approach. A consensus initiative was developed to guide clinicians in the management of patients with DS, with a particular focus on STP‐containing regimens. Methods Based on a literature review and clinical vignette discussions, a nominal group of five international DS experts developed 38 statements across six themes: (i) general principles, (ii) guiding physicians to empower families, (iii) STP as add‐on to specific and non‐specific Dravet ASMs, (iv) FFA in regimens containing STP, (v) CBD in regimens containing STP, and (vi) patient follow‐up during treatment initiation. Statements were scored on a 9‐point Likert scale (1 = strongly disagree, 9 = strongly agree) first by the nominal group and then by an international panel of 59 DS clinicians. Consensus was defined as ≥75% rating ≥7 and/or a median ≥8. Results Thirty‐four of the 38 statements (89%) reached consensus among both the nominal group and the international panel; one did not reach consensus in either, and three reached consensus only among the nominal group. Both panels agreed on the importance of involving families in treatment decisions and follow‐up, as well as on key aspects of polytherapy management, including ASM initiation, treatment adjustments, and adverse event management. Significance This international consensus integrates evidence and clinical expertise to establish shared principles that address a long‐standing gap in the polytherapeutic management of Dravet syndrome. Plain Language Summary Dravet syndrome is a rare and severe form of epilepsy that begins in early childhood, with seizures that often persist throughout life. Because the disease is highly drug resistant, most patients are treated with polytherapy, making clinical management complex for clinicians. This consensus brings together published evidence and expert experience to provide practical guidance on the management of polytherapy in Dravet syndrome, supporting clinicians in optimizing patient care.
Practice Variability in Management of Acute Respiratory Distress Syndrome: Bringing Evidence and Clinician Education to the Bedside Using a Web-Based Teaching Tool
Belda, Thomas E, Gajic, Ognjen, Rabatin, Jeffrey T., Harrison, Barry, Belda, Thomas E., Gajic, Ognjen

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 49 | Issue: 9 | Pages: 1015-1021

10.4187/respcare.04491015 Get It

Inhaled Nitric Oxide for Acute Right-Ventricular Dysfunction After Extrapleural Pneumonectomy
Keegan, Mark T. , Harrison, Barry, Pérez, Evans R. Fernández

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 51 | Issue: 10 | Pages: 1172-1176

10.4187/respcare.06511172 Get It

Developing a platform protocol for clinical trials evaluating interventions that target proposed mechanisms of Long COVID: RECOVER-VITAL
Zimmerman, Kanecia O , Whitley, Richard, O’Brien, Sean, Levy, Bruce D, Maughan, Christine, Cerda, Marta, Olson, Rachel, Bateman, Lucinda , Shibao, Cyndya A., Make, Barry, Knopman, David, Redline, Susan, Jason, Leonard A, Suthar, Mehul S, Low, Phillip, Nolen, Tracy L., Reist, Craig, Berdan, Lisa G. , Baden, Lindsey R, Maughan, Christine , Whitley, Richard J. , O'Brien, Sean, Walt, David R. , Levy, Bruce D, Shibao, Cyndya A , Make, Barry, Knopman, David, Redline, Susan , Jason, Leonard A. , Suthar, Mehul S. , Low, Phillip, Nolen, Tracy L. , Baden, Lindsey R.

Mayo Clinic

Clinical Trials | March 11, 2026 | Volume: 23 | Issue: 4 | Pages: 413-420

10.1177/17407745261422437 | PMID 41789716 Get It

Background: Long COVID, the chronic sequela of SARS-CoV-2 infection, has affected millions of people worldwide. However, its pathogenesis and treatment remain unknown. To address this critical gap, the National Institutes of Health (NIH) developed the Researching COVID to Enhance Recovery (RECOVER) Initiative that included the Viral Persistence and Reactivation, and Immune Dysregulation (RECOVER-VITAL) study as one of the first of five NIH-sponsored, integrated platform protocols to support the rigorous and rapid investigation of potential interventions for Long COVID. Methods: Experts across academia, the NIH, and the community of patients and caregivers were brought together to design the RECOVER-VITAL protocol. We present the challenges and rationale underpinning critical components of this protocol and provide evidence for use of the platform for efficient execution of current and future Long COVID clinical trials. Facets of the RECOVER-VITAL protocol, including inclusion criteria, intervention groups, study procedures, investigation of biomarkers, and endpoints, were carefully crafted to advance the current and future science and operations of Long COVID clinical trials, particularly in the absence of existing data. The initial trial within the RECOVER-VITAL platform evaluated two durations of an antiviral drug, nirmatrelvir/ritonavir, to test the proposed etiology of viral persistence on the Long COVID symptom clusters of autonomic dysfunction, cognitive dysfunction, and exercise intolerance. The primary outcome measures were patient-reported, and secondary outcomes included performance-based measures for each of the symptom clusters of interest. Conclusions: The RECOVER-VITAL platform protocol has substantial implications for the design and conduct of future Long COVID clinical trials.
Very high-dose loop diuretics for worsening heart failure—a randomized pilot trial
Reddy, Yogesh N V, Miranda, William R, Greenlund, Ian M. , Bailey, Kent R, Testani, Jeffrey, Somers, V., Borlaug, Barry A, Pereira, N L, Somers, Virend K. , Charles Jain, C , Oduah, Mary-Tiffany , Adel, Fadi , Somers, Virend K. , Reddy, Yogesh N.V. , Miranda, William R. , Bailey, Kent R. , Testani, Jeffrey M. , Borlaug, Barry A. , Pereira, Naveen L.

Mayo Clinic

European Journal of Heart Failure | March 5, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag069 | PMID 41802270 Get It

Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Mackow, Natalie , Shao, Wanying, Ge, Lizhao , Komarow, Lauren, Jiang, Jianping , Boutzoukas, Angelique , Chen, Liang , Herc, Erica, Doi, Yohei, Arias, Cesar A, Jacob, J, Satlin, Michael J. , Huskins, W Charles, Dhar, Sorabh, Shelburne, Samuel A, Hill, Carol, Sadler, Jacob M., Hill, Bravada M, Greenwood-Quaintance, Kerryl E, Schmidt-Malan, Suzannah M., Patel, Robin, Fowler, Vance G, Tamma, Pranita D, Kreiswirth, Barry N, Group, for the Antibacterial Resistance Leadership, Chambers, Chip, Evans, Scott, Hamasaki, Toshi, Cross, Heather, Harris, Anthony, Pettigrew, Melinda M. , Duin, David van, Boucher, Helen , Dixon, Dennis O., Ghazaryan, Varduhi , Zou, Lanling, Raterman, Erica, Samuel, Tamika, Moon, Kyung, Hanson, Kim, Holland, Thomas, Lodise, Tom, Shelburne, Sam, Banerjee, Ritu, Cosgrove, Sara, Paterson, David, Lautenbach, Ebbing , Mehigan, Maureen, Doernberg, Sarah, Doi, Yohei , Chen, Liang , Boutzoukas, Angelique E , Jiang, Jianping , Doi, Yohei , Albin, Owen , Saade, Elie , Miller, Loren G , Jacob, Jesse T , Satlin, Michael J , Krsak, Martin , Huskins, W Charles , Shelburne, Samuel A , Hill, Carol , Alby, Kevin , Sadler, Jacob M , Hill, Bravada M , Patel, Robin , Fowler, Vance G. , Tamma, Pranita D , van Duin, David , Pettigrew, M M , Evans, Scott R , Ge, Lizhao , Komarow, Lauren , Garcia‐Diaz, Julia , Herc, Erica , Arias, César A. , Albin, Owen , Saade, Elie , Jacob, Jesse T. , Kršák, Martin , Huskins, W. Charles , Dhar, Sorabh , Shelburne, Samuel A. , Hill, Carol , Alby, Kevin , Greenwood‐Quaintance, Kerryl E. , Patel, Robin , Tamma, Pranita D. , Kreiswirth, Barry N , Evans, Scott, Raterman, Erica L., Samuel, Tamika, Banerjee, Ritu , Cosgrove, Sara E. , Paterson, David L. , Mehigan, Maureen

Mayo Clinic

Clinical Infectious Diseases | March 4, 2026 | Volume: 83 | Issue: 1 | Pages: e27-e37

10.1093/cid/ciag160 | PMID 41795867 Get It

Abstract Background Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. Methods A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. Results This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. Conclusions Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.
Impact of contemporary guideline-directed medical therapy on secondary mitral and tricuspid regurgitation in heart failure with reduced ejection fraction
Naser, Jwan A. , Rahme, Serena, Castrichini, M, Ibrahim, Hossam, Scott, Christopher G, Kennedy, Austin M , Eleid, Mackram F., Nkomo, Vuyisile T, Borlaug, Barry A, Lin, G, Scott, Christopher G. , Nkomo, Vuyisile T. , Borlaug, Barry A. , Rahme, Serena J, Scott, Christopher , Nkomo, Vuyisile T , Foley, David A. , Borlaug, Barry A , Sabbah, Michael S. , Kennedy, Austin M , Naser, Jwan A , Castrichini, Matteo , Ibrahim, Hossam H , Eleid, Mackram F. , McKie, Paul M. , Pislaru, Sorin V.

Mayo Clinic

European Journal of Heart Failure | February 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag047 | PMID 41771144 Get It

Abstract Aims We aimed to assess regression and development rates of ≥moderate secondary mitral regurgitation (MR) and tricuspid regurgitation (TR) in patients with heart failure and reduced ejection fraction (HFrEF) receiving contemporary guideline-directed medical therapy (GDMT). Methods Patients with a <1 year diagnosis of HFrEF with mildly (40% ≤ EF < 50%) or moderately (<40%) reduced EF enrolled in GDMT titration programme 2019–2024 were identified. Regression rates of ≥moderate MR/TR to ≤mild and development rates of incident ≥moderate MR/TR were calculated. Results Among 844 patients [median age 64; 68% men; 26% mildly reduced EF; 24% New York Heart Association (NYHA) Class III/IV], 28% had ≥moderate MR and 14% had ≥moderate TR. Over median 7.1 months, 171 (75%) patients with ≥moderate MR and 87 (75%) of patients with ≥moderate TR experienced regression to no/mild MR and TR, respectively. Conversely, over median 13 months, incident ≥moderate MR and TR developed in 5% and 6%, respectively, of patients with no/mild baseline MR and TR. Number of GDMT medications at follow-up was less in patients who did not have MR/TR regression (vs who did) and in patients who developed MR/TR (vs who did not). Patients with NYHA Class I/II received a similar number of GDMT and had a similar rate of MR and TR regression and development vs patients with NYHA Class III/IV. However, patients with mildly reduced EF received less GDMT medications vs patients with moderately reduced EF and experienced less MR regression. Conclusion In patients with a recent diagnosis of HFrEF receiving contemporary GDMT, the majority with ≥moderate secondary MR and TR achieved regression of MR/TR, and the minority without significant baseline MR/TR developed ≥moderate regurgitation at follow-up.
Exercise echocardiography is a useful tool in the diagnosis of HFpEF
O’Sullivan, J., Pugliese, N., Wilcox, I., Kaye, David M, Borlaug, Barry A, Borlaug, Barry A. , O'Sullivan, John F , Borlaug, Barry A , Wilcox, Ian , Gargani, Luna , Kaye, David M.

Mayo Clinic

European Journal of Heart Failure | February 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ejhf/xuag045 | PMID 41771108 Get It

Comparison of Immune Cell Transfection by Different Vaccine Vectors After Intradermal Injection
Liu, J, Hinson, Destin T , Hansen, M. A, Keulen, Virginia P. Van , Parrett, Brian J. , Pease, Larry R. , Barry, Michael A., Liu, Jiani , Liu, Jiani , Barry, Michael A

Mayo Clinic

Vaccines | February 16, 2026 | Volume: 14 | Issue: 2 | Pages: 185

10.3390/vaccines14020185 | PMID 41746105 Get It

Background/Objectives: Antigen presenting cells (APCs) and immune cells have unique properties to drive or suppress immune responses. They are therefore key targets for the expression of vaccine antigens or transgene proteins. To better determine the utility of different molecular therapies to modify these cells, mRNA and DNA-based molecular therapy vectors were compared for their ability to genetically modify immune cells after intradermal injections in mice. DNA-based vectors included naked plasmid DNA, plasmid packaged in lipid nanoparticles (LNPs), and replication-defective adenovirus (Ad) vectors. mRNA delivery was mediated by packaging into LNPs like those used in COVID-19 vaccines. Methods: Each vector was used to deliver Cre recombinase into Cre reporter mice whose cells were activated to express green fluorescent protein (GFP) and firefly luciferase after Cre recombination. The mice were injected intradermally (ID) near the base of their tail at a site that drains into the inguinal lymph node. Luciferase activity was imaged in the living mice 1 or 4 days after vector injection. The animals were then euthanized, and luciferase activity was imaged in the draining inguinal lymph node. Cells were prepared from the intradermal injection site and from the draining lymph node to determine which immune cells were genetically modified by phenotyping CD45, CD3, and CD11b GFP-positive cells by flow cytometry. Given that the skin uniquely contains Langerhans dendritic cells, these CD207+ cells were also phenotyped in skin samples and in the draining lymph node. Results: In both the skin and in the draining lymph node, the rank order of luciferase and GFP activation by the vectors were: (1) Ad; (2) mRNA-LNP; (3) DNA-LNP; and (4) naked DNA. Only mRNA-LNP and Ad vectors mediated obvious luciferase activity in the living animals and in the draining lymph nodes by imaging. Notably, both vectors appeared to leak from the ID injection site and not only modify the draining lymph node but also strongly modify the livers of the mice. Naked DNA and DNA-LNP mediated detectable GFP activation in the skin and draining lymph node in some mice, but this activity was low and did not reach statistical significance when compared to PBS-treated animals. mRNA-LNPs and Ad both mediated significant Cre delivery in CD45+, CD3+, CD11b+, and CD207+ immune cells in the skin and in the lymph node, with adenovirus mediating consistently higher levels of expression in all of the tested cells. Conclusions: These data indicate that mRNA-LNP and Ad vectors mediate stronger modification of skin and lymph node immune cells after intradermal injections. Naked DNA and DNA-LNPs were markedly less potent at this activity than the other vectors. These data are consistent with the higher vaccine potency of mRNA-LNP and Ad vectors and suggest that approaches that increase targeting of immune cell subsets may have utility to increase efficacy while also reducing off-target modification of tissues like the liver.